Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02984969
Other study ID # STC-2016-16sRNA
Secondary ID
Status Recruiting
Phase N/A
First received November 20, 2016
Last updated December 4, 2016
Start date July 2016
Est. completion date February 2017

Study information

Verified date December 2016
Source Jinling Hospital, China
Contact Jianfeng Gong, PhD
Phone +86-25-80860036
Email jinlingh_gongjf@126.com
Is FDA regulated No
Health authority China: Ministry of Health
Study type Observational

Clinical Trial Summary

Constipation is a frequent, chronic gastroenterological problem that has many varied symptoms and thus has several clinical definitions. According to the Rome III criteria for chronic constipation, almost 16% of all adults are affected by chronic constipation worldwide, and it is more prevalent and symptomatic in women and elderly people. Slow transit constipation (STC) is the major category and is characterized by a decreased rate of colonic transit.

Recently, many researchers have focused on the relationship between intestinal microbiota and constipation and have demonstrated that intestinal microbiota contribute to the pathophysiology of functional gastrointestinal disorders.

Thus, there is a need for an improved understanding of gut microbiota composition in constipation patients and for the potential role played by the gut microbiota in the etiology of STC.To achieve this goal the investigators characterized and compared the intestinal microbiota among carefully selected patients with constipation that were clinically categorized based on Rome III criteria, and healthy controls using high throughput pyrosequencing of the 16S rRNA gene and a conservative approach to detect quantitative changes in the relative abundances of taxa.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date February 2017
Est. primary completion date November 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Chronic constipation according to Rome III criteria, defined as two or fewer spontaneous, complete bowel movements (SCBMs) per week for a minimum of 6 months;

2. Age > 18 years;

3. BMI: 18.5-25 kg/m2;

4. Slow colonic transit confirmed by colonic transit test (colonic transit time (CTT) > 48 hours);

5. Normal anorectal manometry, with no evidence of dyssynergia and confirmed ability to expel rectal balloon;

6. No radiographic evidence of functional (i.e. pelvic floor dyssynergia) or anatomical (i.e. significant rectocele and intussusception) impediment to the expulsion of the radio-opaque contrast;

7. Disease duration > 1 year;

8. Traditional treatment with dietary modification, laxatives (including osmotic and stimulant laxatives), and biofeedback tried over the past 6 months without success;

Exclusion Criteria:

1. Bowel constipation due to innate factor (i.e. megacolon) or secondary interventions (i.e. drugs, endocrine, metabolic, neurologic or psychologic disorders);

2. History or evidence of gastrointestinal diseases (i.e. obstruction, cancer, inflammatory bowel diseases) ;

3. Previous abdominal surgery, except cholecystectomy, appendicectomy, tubal ligation and cesarean section;

4. Previous proctological or perianal surgery;

5. A constipation condition meeting the Rome III criteria for IBS or functional abdominal pain syndrome;

6. Pregnant or breast-feeding women;

7. Infection with enteric pathogen;

8. Usage of probiotics, prebiotics and/or synbiotics within the last month;

9. Usage of antibiotics and/or PPIs within the last 3 months;

10. Smoking or alcohol addiction within the last 3 months;

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
China Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Jinling Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fecal microbiota sequence The fecal samples and isolated microbiota samples were frozen immediately and underwent DNA extraction using standard methods at BGI-Shenzhen Within a week after enroll Yes
Secondary Stool short-chain fatty acids (SCFAs) The stool short-chain fatty acids (SCFAs) were extracted and quantitatively analysed by gas chromatography-mass spectrometry (GC-MS) Within a week after enroll Yes
See also
  Status Clinical Trial Phase
Completed NCT02844426 - Effect of a Synbiotic on Symptoms of Patients With STC Phase 2
Recruiting NCT02526849 - Efficacy and Safety of Fecal Microbiota Transplantation for Slow Transit Constipation Phase 2
Recruiting NCT05352074 - STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation N/A
Recruiting NCT02291354 - Evaluating the Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Slow Transit Constipation Phase 2
Active, not recruiting NCT02301221 - Effect of Fecal Microbiota Transplantation in Slow Transit Constipation Phase 2
Active, not recruiting NCT05718505 - Comparison of the Atmo Motility Gas Capsule System to the Reference Standard N/A
Recruiting NCT02676388 - Freeze-dried vs Fresh Fecal Microbiota Transplantation in Patients With Slow Transit Constipation Phase 2